[go: up one dir, main page]

TN2009000094A1 - Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors - Google Patents

Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors

Info

Publication number
TN2009000094A1
TN2009000094A1 TN2009000094A TN2009000094A TN2009000094A1 TN 2009000094 A1 TN2009000094 A1 TN 2009000094A1 TN 2009000094 A TN2009000094 A TN 2009000094A TN 2009000094 A TN2009000094 A TN 2009000094A TN 2009000094 A1 TN2009000094 A1 TN 2009000094A1
Authority
TN
Tunisia
Prior art keywords
leukemia
tyrosine kinase
abl tyrosine
cmin
bcr
Prior art date
Application number
TN2009000094A
Other languages
English (en)
Inventor
Insa Gathmann
Francois-Xavier Mahon
Stephane Picard
Yanfeng Wang
Mathieu Molimard
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39092883&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000094(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2009000094A1 publication Critical patent/TN2009000094A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Ecology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TN2009000094A 2006-09-22 2009-03-19 Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors TN2009000094A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82662206P 2006-09-22 2006-09-22
US82827806P 2006-10-05 2006-10-05
PCT/US2007/078978 WO2008036792A2 (fr) 2006-09-22 2007-09-20 Procédé d'optimisation de traitement de la leucémie philadelphie positive avec des inhibiteurs de tyrosine kinase abl

Publications (1)

Publication Number Publication Date
TN2009000094A1 true TN2009000094A1 (en) 2010-08-19

Family

ID=39092883

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2009000094A TN2009000094A1 (en) 2006-09-22 2009-03-19 Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors

Country Status (24)

Country Link
US (2) US20090281113A1 (fr)
EP (2) EP2068938B1 (fr)
JP (1) JP5735742B2 (fr)
KR (1) KR20090065512A (fr)
AT (1) ATE495761T1 (fr)
AU (1) AU2007299764B2 (fr)
BR (1) BRPI0717099A2 (fr)
CA (1) CA2662977A1 (fr)
CL (1) CL2007002725A1 (fr)
CY (1) CY1111356T1 (fr)
DE (1) DE602007012122D1 (fr)
DK (1) DK2068938T3 (fr)
HR (1) HRP20110250T1 (fr)
IL (1) IL197296A (fr)
MA (1) MA30786B1 (fr)
MX (1) MX2009003082A (fr)
NO (1) NO20091490L (fr)
NZ (1) NZ575113A (fr)
PL (1) PL2068938T3 (fr)
PT (1) PT2068938E (fr)
TN (1) TN2009000094A1 (fr)
TW (1) TWI398251B (fr)
WO (1) WO2008036792A2 (fr)
ZA (1) ZA200901220B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009094360A1 (fr) 2008-01-23 2009-07-30 Novartis Ag Procédé d'optimisation du traitement de maladies prolifératives à médiation par récepteur à tyrosine kinase kit avec de l'imatinib
JP2012510470A (ja) * 2008-12-01 2012-05-10 ノバルティス アーゲー メシル酸イマチニブを用いたフィラデルフィア陽性白血病の処置を最適化する方法
US20110046919A1 (en) 2009-03-02 2011-02-24 Juliesta Elaine Sylvester Method for accurate measurement of enzyme activities
FR2943418A1 (fr) * 2009-03-17 2010-09-24 Centre Nat Rech Scient Procedes de mesure de la quantite intracellulaire de molecules d'interet intrinsequement fluorescentes par cytometrie en flux et leurs applications
CN105765065A (zh) * 2013-11-22 2016-07-13 日本国成育医疗研究中心 急性成淋巴细胞性白血病的新型嵌合基因atf7ip-pdgfrb
WO2017007547A1 (fr) 2015-07-07 2017-01-12 Codexis, Inc. Nouveaux variants de p450-bm3 ayant une activité améliorée
IT201900008808A1 (it) 2019-06-13 2020-12-13 Univ Ca Foscari Metodo per la determinazione della concentrazione di 4-[(4-metil-1-piperazinil)metil]-n-(4-metil-3-{[4-(3-piridinil)-2-pirimidinil]-ammino}fenil)benzammide(imatinib) in campioni di plasma
CN114994213A (zh) * 2022-06-28 2022-09-02 北京赛诺浦生物技术有限公司 一种测定人血浆中抗肿瘤药物酪氨酸激酶抑制血药浓度的试剂盒及测定方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
PL215901B1 (pl) 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
GB0202873D0 (en) 2002-02-07 2002-03-27 Novartis Ag Organic compounds
JP2005522221A (ja) * 2002-04-17 2005-07-28 ノバルティス アクチエンゲゼルシャフト チロシンキナーゼ阻害剤に対する患者応答性の予測方法
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
BRPI0511978A (pt) 2004-06-10 2008-01-22 Irm Llc compostos e composições como inibidores de proteìnas quinases
GB0421525D0 (en) 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
MY148074A (en) 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant

Also Published As

Publication number Publication date
AU2007299764B2 (en) 2011-10-13
ZA200901220B (en) 2010-02-24
EP2068938B1 (fr) 2011-01-19
IL197296A (en) 2011-11-30
KR20090065512A (ko) 2009-06-22
US20170007605A1 (en) 2017-01-12
JP2010504353A (ja) 2010-02-12
AU2007299764A1 (en) 2008-03-27
DK2068938T3 (da) 2011-04-04
HK1133194A1 (en) 2010-03-19
NZ575113A (en) 2012-03-30
CL2007002725A1 (es) 2008-05-16
US20090281113A1 (en) 2009-11-12
JP5735742B2 (ja) 2015-06-17
BRPI0717099A2 (pt) 2013-10-15
TWI398251B (zh) 2013-06-11
MA30786B1 (fr) 2009-10-01
NO20091490L (no) 2009-06-15
PT2068938E (pt) 2011-03-23
CY1111356T1 (el) 2015-08-05
TW200822926A (en) 2008-06-01
CA2662977A1 (fr) 2008-03-27
DE602007012122D1 (de) 2011-03-03
EP2068938A2 (fr) 2009-06-17
ATE495761T1 (de) 2011-02-15
PL2068938T3 (pl) 2011-06-30
WO2008036792A3 (fr) 2008-11-13
IL197296A0 (en) 2011-08-01
RU2009114856A (ru) 2010-10-27
EP2251042A2 (fr) 2010-11-17
MX2009003082A (es) 2009-04-01
EP2251042A3 (fr) 2012-05-02
WO2008036792A2 (fr) 2008-03-27
HRP20110250T1 (hr) 2011-05-31

Similar Documents

Publication Publication Date Title
TN2009000094A1 (en) Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors
Cappuzzo et al. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)
Zhu et al. Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals
EA201190042A1 (ru) Имидазопиразиновые ингибиторы тирозинкиназы syk
JP2005529162A (ja) キナーゼインヒビターを使用して癌を処置する方法
KR102425655B1 (ko) 수면 개선 방법
Bonifacio et al. Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy
EA201071422A1 (ru) Способы лечения заболеваний, связанных с мейотическим кинезином
WO2010066891A3 (fr) Méthode de prédiction de la réponse à un traitement à l'aide d'inhibiteurs de tyrosine kinase ciblant la protéine de fusion bcr-abl chez des patients atteints de leucémie myéloïde chronique
RU2010101634A (ru) Способ оптимизации лечения хронического миелолейкоза с помощью ингибиторов трирозинкиназы abi
Motegi et al. Role of endothelin‐1/endothelin receptor signaling in fibrosis and calcification in nephrogenic systemic fibrosis
ATE402739T1 (de) Behandlung von entzündungen
RU2020134183A (ru) Способ ингибирования пути egf/egfr в комбинации с ингибиторами тирозинкиназы
CN115175678B (zh) 使用btk抑制剂及其组合治疗dlbcl的方法
Eberle et al. In cancer cell lines inhibition of SCF/c-Kit pathway leads to radiosensitization only when SCF is strongly over-expressed
SG163614A1 (en) Colon cancer related gene tom34
US20110224224A1 (en) Method of Optimizing the Treatment of Philadelphia-Positive Leukemia with Imatinib Mesylate
Ozgur-Akdemir et al. Imatinib mesylate (Gleevec) as protein-tyrosine kinase inhibitor elicits smooth muscle relaxation in isolated human prostatic tissue
TW200507828A (en) Method for treatment of chemotherapy-induced diarrhea
Rodriguez et al. AB0165 THE ROLE OF CXCL4, CXCL8 AND GDF-15 IN SYSTEMIC SCLEROSIS
RU2483732C2 (ru) СПОСОБ ОПТИМИЗАЦИИ ЛЕЧЕНИЯ ЛЕЙКОЗА, ПОЛОЖИТЕЛЬНОГО ПО ФИЛАДЕЛЬФИЙСКОЙ ХРОМОСОМЕ, ИНГИБИТОРАМИ Ab1-ТИРОЗИНКИНАЗЫ
CN102526734A (zh) 治疗年龄相关性听力损失的药物组合物及其应用
Chen et al. The Role of Abnormal Expression of Clock Gene DBP Mediated by Gut Microbiota Dysbiosis in Cognitive Dysfunction in ESRD and the Underlying Mechanism: PO2485
Pianka et al. GENE-38. IDH1MUT INDUCES N6-METHYLADENOSINE (m6A) RNA HYPERMETHYLATION VIA D-2-HG IN GLIOMA
DeLalio et al. Circadian Cycle Exaggerates Sympathoexcitatory Responses to Activation of Chemosensitive Renal Sensory Nerves: PO2486